 LAVAL, Quebec--BUSINESS WIRE--BELLUS Health Inc. Nasdaq:BLU; TSX:BLU BELLUS Health or the Company, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors. Dr. Mezzanotte brings decades of vast development and commercial experience to the Board, including the development and approval of 30 products 